CAS Number1316214-52-4
Synonyms2-(diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; ACY-1215; Ricolinostat [USAN]; ACY-63; Rocilinostat; ACY1215; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; cc-661; Rocilinostat (ACY-1215); Ricolinostat
Molecular FormulaC24H27N5O3
Molecular Weight433.503
Density1.2±0.1 g/cm3
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 1316214-52-4 |
| Catalog No. | 2A-1170398 |
| Chinese Name | Ricolinostat (ACY-1215) |
| Synonyms | 2-(diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; ACY-1215; Ricolinostat [USAN]; ACY-63; Rocilinostat; ACY1215; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; cc-661; Rocilinostat (ACY-1215); Ricolinostat |
| Molecular Formula | C24H27N5O3 |
| Molecular Weight | 433.503 |
| Density | 1.2±0.1 g/cm3 |
| Water Solubility | Insuluble (4.3E-3 g/L) (25 ºC) |
| Storage Condition | Room temperature, dry, sealed |
| Application | Ricolinostat (ACY-1215) is a potent, selective HDAC6 inhibitor with an IC50 of 5 nM. ACY-1215 also inhibits HDAC1, HDAC2 and HDAC3 with IC50 of 58, 48 and 51 nM respectively. |
| HTC | 2933599090 |
| PubChem ID | 125005606 |
| SMILES | O=C(CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1)NO |
| InChI | InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30) |
| InChI Key | QGZYDVAGYRLSKP-UHFFFAOYSA-N |
| Use of | Ricolinostat (ACY-1215) is a potent and selective HDAC6 inhibitor, with an IC50 of 5 nM. ACY-1215 also inhibits HDAC1, HDAC2, and HDAC3 with IC50s of 58, 48, and 51 nM, respectively. Properties Name N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide Synonym More Synonyms Ricolinostat (ACY-1215) Biological Activity Description Ricolinostat (ACY-1215) is a potent and selective HDAC6 inhibitor, with an IC50 of 5 nM. ACY-1215 also inhibits HDAC1, HDAC2, and HDAC3 with IC50s of 58, 48, and 51 nM, respectively. Related Catalog Signaling Pathways >> Cell Cycle/DNA Damage >> HDAC Signaling Pathways >> Epigenetics >> HDAC Research Areas >> Cancer HDAC6:4.7 nM (IC50) HDAC2:48 nM (IC50) HDAC3:51 nM (IC50) HDAC1:58 nM (IC50) HDAC8:100 nM (IC50) HDAC7:1400 nM (IC50) HDAC5:5000 nM (IC50) HDAC4:7000 nM (IC50) In Vitro Ricolinostat (ACY-1215) has slight activity against HDAC8 (IC50=0.1 μM), and has minimal activity (IC50>1 μM) against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1, and Sirtuin2. The effect of Ricolinostat (ACY-1215) on multiple myeloma (MM) cell viability is determined with MTT assays using MM cell lines. Exposure of MM cell lines for 48 hours results in dose-dependent decreased viability, with IC50 values ranging from 2-8μM. Ricolinostat (ACY-1215) demonstrates significant activity in the MM Bortezomib-resistant cell line (ANBL-6.BR), demonstrating the ability of Ricolinostat (ACY-1215) to overcome Bortezomib resistance[1]. In Vivo Mice treated with Ricolinostat (ACY-1215), Bortezomib, or Ricolinostat plus Bortezomib show a significant delay in tumor growth (P=0.01, P=0.006, and P<0.0001, respectively). Combined treatment with Ricolinostat and Bortezomib shows significant suppression of tumor growth and significantly prolonged overall survival (OS) compare with the control group (17 days in the control vs 40 days in the combination-treated group, P<0.0001) and the Ricolinostat (ACY-1215)-treated group (22 days in the Bortezomib group vs 40 days in the combination-treated group, P<0.0001). Weight loss in the combination-treated group is between 4% and 12% compare with the same-day control group values during treatment, with complete recovery after the last injection. As is observed in the plasmacytoma model, a significant therapeutic advantage is found by combining Ricolinostat with Bortezomib compare with either agent alone[1]. References [1]. Santo L, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012 Mar 15;119(11):2579-89. Chemical & Physical Properties Molecular Formula C24H27N5O3 Exact Mass 433.211395 PSA 114.43000 Index of Refraction 1.620 InChIKey QGZYDVAGYRLSKP-UHFFFAOYSA-N Safety Information Hazard Codes Xi HS Code 2933599090 Synthetic Route 7-({2-[(1-Methy... CAS#:1316216-07-5 Ricolinostat (A... CAS#:1316214-52-4 Ethyl 2-chlorop... CAS#:89793-12-4 Ricolinostat (A... CAS#:1316214-52-4 CAS#:74497-02-2 Ricolinostat (A... CAS#:1316214-52-4 Precursor & DownStream Precursor 6 CAS#:1316216-07-5 7-({2-[(1-Methy... CAS#:89793-12-4 Ethyl 2-chlorop... CAS#:864172-93-0 5-Pyrimidinecar... CAS#:95928-49-7 Ethyl 2-oxo-1,2... DownStream 0 |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| 4-METHYL-1,3-PENTADIENE | 926-56-7 | 2A-1170392 |
| mugineic acid | 69199-37-7 | 2A-1170393 |
| GW7647 | 265129-71-3 | 2A-1170394 |
| 5-((7-BENZYLOXYQUINAZOLIN-4-YL)AMINO)-4-FLUORO-2-METHYLPHENOL HYDROCHLORIDE | 324077-30-7 | 2A-1170395 |
| ZM 306416 | 690206-97-4 | 2A-1170396 |
| SCH900776 | 891494-63-6 | 2A-1170400 |
| OSI-027 | 936890-98-1 | 2A-1170401 |
| TENOVIN-1 | 380315-80-0 | 2A-1170402 |
| HA14-1 | 65673-63-4 | 2A-1170404 |
| SMI-4a | 327033-36-3 | 2A-1170405 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS